



Office de la Propriété
Intellectuelle
du Canada

Un organisme
d'Industrie Canada

Canadian
Intellectual Property
Office

An agency of
Industry Canada

CA 2509831 A1 2004/07/01

(21) **2 509 831**

(12) **DEMANDE DE BREVET CANADIEN
CANADIAN PATENT APPLICATION**

(13) **A1**

(86) Date de dépôt PCT/PCT Filing Date: 2003/10/31

(87) Date publication PCT/PCT Publication Date: 2004/07/01

(85) Entrée phase nationale/National Entry: 2005/06/13

(86) N° demande PCT/PCT Application No.: IB 2003/005282

(87) N° publication PCT/PCT Publication No.: 2004/055180

(30) Priorité/Priority: 2002/12/13 (02293085.3) EP

(51) Cl.Int.⁷/Int.Cl.⁷ C12N 9/88, A61K 48/00

(71) Demandeur/Applicant:
CENTRE NATIONAL DE LA RECHERCHE
SCIENTIFIQUE (CNRS), FR

(72) Inventeurs/Inventors:
BOUTIN, PHILIPPE, FR;
DUBOIS, SEVERINE, FR;
DINA, CHRISTIAN, FR;
FROGUEL, PHILIPPE, FR


(74) Agent: OGILVY RENAULT LLP/S.E.N.C.R.L.,S.R.L.

(54) Titre : PROCEDE DE DIAGNOSTIC DE L'OBESITE

(54) Title: METHOD OF DIAGNOSIS OF OBESITY

(57) **Abrégé/Abstract:**

The invention relates to new methods of diagnosis and therapy of obesity, in particular morbid obesity, based on the identification of polymorphisms in the 5' region of the gad2 gene.



(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
1 July 2004 (01.07.2004)

PCT

(10) International Publication Number
WO 2004/055180 A1

(51) International Patent Classification⁷: **C12N 9/88**,
A01K 67/207, A61K 48/00

[FR/FR]; 104, Avenue de la Dhuys, F-93170 Bagnolet (FR).

(21) International Application Number:
PCT/IB2003/005282

(74) Agents: **MARTIN, Jean-Jacques** et al.; Cabinet Regimbeau, 20, rue de Chazelles, F-75847 Paris Cedex 17 (FR).

(22) International Filing Date: 31 October 2003 (31.10.2003)

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
02293085.3 13 December 2002 (13.12.2002) EP

(84) Designated States (*regional*): ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): **CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)** [FR/FR]; 3, Rue Michel Ange, F-75016 Paris (FR).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **BOUTIN, Philippe** [FR/FR]; 133, Bois D'Achelles, F-59200 Tourcoing (FR). **DUBOIS, Séverine** [FR/FR]; 43, Avenue des Lilas, F-80800 Vecquemont (FR). **DINA, Christian** [FR/FR]; 16, rue Saulnier, F-75009 Paris (FR). **FROGUEL, Philippe**

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: METHOD OF DIAGNOSIS OF OBESITY

(57) Abstract: The invention relates to new methods of diagnosis and therapy of obesity, in particular morbid obesity, based on the identification of polymorphisms in the 5' region of the *gad2* gene.

WO 2004/055180 A1

METHOD OF DIAGNOSIS OF OBESITY

The invention is in the field of human genetics and relates to new methods
5 of diagnosis and therapy of obesity, in particular morbid obesity, based on the identification of polymorphisms in the 5' region of the *gad2* gene.

Morbid obesity is a serious disease process, in which the accumulation of fatty tissue on the body becomes excessive, interferes with, or injures the other bodily organs, and creates (or predictably will create) serious and life-threatening
10 health problems, which are called co-morbidities.

It is said that people are morbidly obese when their Body Mass Index (BMI = height (cm) / (mass (kg))²) is equal to or over 40.

Numerous scientific studies have established that there is a genetic predisposition to morbid obesity.

15 A region of the chromosome 10 has been involved in obesity (Hager et al, Nature Genetics 1998; 20:304-38.), which has been recently confirmed in a cohort of German young obese subjects (Hinney et al. 2000, Journal of Clinical Endocrinology and Metabolism 2000 ; 85 (8): 2962-5), as well as in White Caucasians and in African Americans (Price et al. 2001, Diabetologia 1999, 42 :
20 555-9), and in the old order Amish (Hsueh et al. 2001, The Journal of Clinical Endocrinology and Metabolism 2001 ; 86(3) : 1199-1205).

Three new single nucleotide polymorphisms (SNPs) have been identified in the frame of the invention, located in this region, and more particularly in the 5' region of the *gad2* gene. These SNPs show positive association with obesity in
25 morbidly obese subjects, while other SNPS in this region do not show this association.

In the frame of the present invention, by *gad2* gene is meant to indicate a gene whose coding sequence is represented by SEQ ID N° 1.

The 5' flanking region of *gad2* gene is meant to indicate the region
30 comprising nucleotides 1-2379 of SEQ ID N° 2, and especially the region consisting in nucleotides 1-2379 of SEQ ID N° 2. Nucleotides 2380-2382 of SEQ ID N° 2 represent the start codon of the *gad2* gene (ATG).

Thus, in a first embodiment, the invention relates to a method for diagnosing a predisposition for obesity, and in particular morbid obesity, in a human subject which comprises determining whether there is a germline alteration in the sequence of the 5' flanking region of the *gad2* gene, wherein said alteration is the presence of
5 at least one of the following mutations: -243 A>G at nucleotide 2137 of SEQ ID N° 2, -1.6kb G>A at nucleotide 780 of SEQ ID N° 2, -2004 A>T at nucleotide 376 of SEQ ID N° 2, said alteration being indicative of a predisposition to obesity.

The 5' flanking region of the *gad2* gene is represented by nucleotides 1-2379 of SEQ ID N° 2, and the SNPs according to the invention are located at
10 nucleotides 376 (presence of a T in predisposed patients, and a A in non-predisposed patients), 780 (presence of a A in predisposed patients, and a G in non-predisposed patients), and 2137 (presence of a G in predisposed patients, and a A in non-predisposed patients) of SEQ ID N° 2.

The invention relates more generally to the study of the 5' promoter region
15 of the *gad2* gene. Indeed, the inventors have demonstrated that the presence of the specific SNPs indicated in the present application leads to increased binding of nuclear factors to the 5' region of the *gad2* gene, thus leading to an increase in transcription.

It is thus credible to speculate that other modifications in the promoter
20 region of the *gad2* gene, leading to a higher expression of the GAD2 protein will also lead to predisposition to obesity, due to increase in the GABA pool. Due to the orexigenic effect of GABA, this may alter feeding behavior.

Thus, in one embodiment, the invention relates to a method for diagnosing a predisposition for obesity in a human subject, wherein the level of an expression
25 product of the *gad2* gene in said sample is investigated.

The expression products according to the invention are meant to comprise RNA or protein, or what could be called "secondary" expression product, such as GABA. The latest is indeed not really an expression product of the *gad2* gene, but increase in the production of GAD2 protein leads to increase in the GABA
30 concentration.

Alteration of mRNA expression can be detected by any techniques known in the art. These include Northern blot analysis, PCR amplification and RNase protection

In one embodiment, mRNA of the sample is contacted with a *gad2* gene probe under conditions suitable for hybridization of said probe to a RNA corresponding to said *gad2* gene and hybridization of said probe is determined, and the level of signal after hybridization is compared with a standard (reference) signal
5 (which is obtained from either a non-obese patient, or an obese patient).

The hybridization complex emits a signal, which may be due to the labeling of the probe, or of the mRNA. The different labels that may be used are well known to the person skilled in the art, and one can cite ^{32}P , ^{33}P , ^{35}S , ^3H or ^{125}I . Non radioactive labels may be selected from ligands as biotin, avidin, streptavidin,
10 dioxygenin, haptens, dyes, luminescent agents like radioluminescent, chemoluminescent, bioluminescent, fluorescent or phosphorescent agents.

In order to identify the SNPs mentioned in the present application, it is possible to contact a *gad2* gene 5' region probe with genomic DNA isolated from said sample under conditions suitable for hybridization of said probe to said gene
15 and hybridization of said probe is determined.

Said *gad2* gene 5' region probe is either a "wild-type" DNA, (i.e. the searched SNP is not present on the probe, and hybridization occurs when no SNP according to the invention is present on the DNA in the sample) or a "mutant" one (i.e. carrying the searched SNP, and hybridization only occurs if the SNP is present
20 on the DNA in the sample).

The person skilled in the art knows the techniques to determine the allele specific probes to use in this embodiment, their lengths, or the hybridization conditions. High stringency conditions are preferable in order to prevent false positives, for example under high stringency conditions of 0.2 x SSC and 0.1 %
25 SDS at 55-65°C, or under conditions as described below.

The stringent hybridization conditions may be defined as described in Sambrook et al. ((1989) Molecular cloning : a laboratory manual. 2nd Ed. Cold Spring Harbor Lab., Cold Spring Harbor, New York.), with the following conditions: 5 x or 6 x SCC, 50-65°C. Highly stringent conditions that can also be
30 used for hybridization are defined with the following conditions: 6 X SSC, 60-65°C.

Hybridization ADN-ADN or ADN-ARN may be performed in two steps: (1) prehybridization at 42°C pendant 3 h in phosphate buffer (20 mM, pH 7.5)

containing 5 or 6 x SSC (1 x SSC corresponding to a solution 0.15 M NaCl + 0.015 M sodium citrate), 50 % formamide, 7 % sodium dodecyl sulfate (SDS), 10 x Denhardt's, 5 % dextran sulfate et 1 % salmon sperm DNA; (2) hybridization during up to 20 at a temperature of 50-65°C, more preferably 60-65°C followed by
5 different washes (about 20 minutes at in 2 x SSC + 2 % SDS, then 0.1 x SSC + 0.1 % SDS). The last wash is performed in 0.2 x SSC + 0.1 % SDS for about 30 minutes at about 50-65°C, and/or in 0.1 x SSC + 0.1 % SDS at the same temperature. These high stringency hybridization conditions may be adapted by a person skilled in the art. Indeed, the person skilled in the art is able to determine the
10 best stringency conditions by varying the concentrations in SSC and SDS and the temperature of hybridization and washings.

In another embodiment, said expression product is the polypeptide encoded by the *gad2* gene in said sample. In particular, said polypeptide may be detected by immunoblotting or immunocytochemistry.

15 Antibodies specific for GAD2 can be used to detect increased GAD2 expression. Immunological assays can be done in any convenient formats known in the art. These include Western blots, immunohistochemical assays and ELISA assays.

Thus, antibodies that react with the the GAD2 polypeptide, as well as
20 reactive fragments of such antibodies, are also encompassed within the scope of the present invention. The antibodies may be polyclonal, monoclonal, recombinant, chimeric, single-chain and/or bispecific. In preferred embodiment, the antibody or fragment thereof will either be of human origin, or will be "humanized", i.e., prepared so as to prevent or minimize an immune reaction to the antibody when
25 administered to a patient.

The antibody fragment may be any fragment that is reactive with the polypeptides of the present invention. the invention also encompasses the hybridomas generated by presenting the polypeptide according to the invention or a fragment thereof as an antigen to a selected mammal, followed by fusing cells (e.g.,
30 spleen cells) of the mammal with certain cancer cells to create immortalized cell lines by known techniques, such as the technique of Köhler et Milstein (1975 Nature 256, 495).

The antibodies according to the invention are, for example, chimeric antibodies, humanized antibodies, Fab ou F(ab')₂ fragments. They may be immunoconjugates or labeled antibodies, for detection purposes.

5 In another embodiment, the invention is performed by determining whether there is an alteration in the germline sequence of the *gad2* gene 5' region in said sample by observing shifts in electrophoretic mobility of single-stranded DNA from said sample on denaturing or non-denaturing polyacrylamide gels. Said single-stranded nucleic acids may be obtained after amplification of the genomic DNA,
10 using suitable primers, and denaturation (the gel and electrophoresis conditions are usually denaturing for such a purpose).

In another embodiment, the invention is performed by amplification of all or part of the *gad2* gene 5' region from said sample, and determination of the sequence
15 of said amplified DNA, for example by chain termination extension.

In another embodiment, allele specific oligonucleotide primers are employed to determine whether a specific *gad2* mutant allele is present in said sample, the amplification only occurring in this case. This method is well known in the art.

20 In another embodiment, all or part of the *gad2* gene 5' region from said sample is cloned to produce a cloned sequence and the sequence of said cloned sequence is determined. The cloning is performed in vectors known in the art, such as pUC or pBR vectors.

25 In general, the invention relates to a method for determining a predisposition to obesity, in particular morbid obesity, in a subject, from a sample of said subject, which comprises determining whether there is a mismatch between (1) the 5' region of the *gad2* gene genomic DNA isolated from said sample, and (2) a nucleic acid probe complementary to human wild-type 5' region of the *gad2* gene DNA, as
30 represented by SEQ ID N° 2, when molecules (1) and (2) are hybridized to each other to form a duplex, and said mismatch being due to the presence of at least one of the 3 identified SNPs, present et nucleotides 376, 780 or 2137 of SEQ ID N° 2.

In another embodiment, the invention relates to a method wherein amplification of *gad2* gene 5' flanking region sequences in said sample is carried out and hybridization of the amplified sequences to one or more nucleic acid probes issued from the wild-type *gad2* gene 5' flanking region sequence (as represented in
5 SEQ ID N° 2) or a mutant *gad2* gene 5' flanking region sequence (in which at least one of the three SNPs located at nucleotides 376, 780 or 2137 of SEQ ID N° 2 is present), is determined.

The invention also relates to a method which comprises determining *in situ* hybridization of the *gad2* gene 5' flanking region in said sample with one or more
10 nucleic acid probes issued from a wild-type or a mutant *gad2* gene 5' flanking region sequence.

In another embodiment, the invention is aimed at a primer or probe for detecting a predisposition for obesity selected from SEQ ID No 4 to 15.

It also encompasses a kit for detecting a predisposition for obesity comprising a
15 set of primers or probes consisting of SEQ ID No 4, 5, 8, 9, 12 and 13 or a set of primers or probes consisting of SEQ ID No 6, 7, 10, 11, 14, and 15.

This kit may further comprise a primer or probe allowing detection of a protective haplotype consisting of 10 to 30 consecutive nucleotides of SEQ ID No 16 or 17 or of a sequence complementary thereof.

20 The invention opens up a new area in the treatment and/or prevention of obesity, in particular morbid obesity, especially for patient in families where genetic susceptibility is suspected.

Indeed, the presence of the SNPs in the 5' region of the *gad2* gene, and the data showing increased binding of nuclear factors to said region when the
25 polymorphisms identified in the frame of the invention are present, make it likely and credible that presence of these polymorphisms increase expression of *gad2*, probably through increased transcription. Furthermore, increased activity of *gad2* gene leads to increase of the GABA pool, of the orexigenic effect of GABA, which may alter feeding behavior and contribute to the development of morbid obesity for
30 the carriers of the identified mutations.

Thus, the invention also relates to a method for screening potential obesity drugs which comprises: combining (i) a compound suspected of being a obesity drug, (ii) a GAD2 polypeptide and determining the amount of binding of the GAD2

polypeptide to said compound. Indeed, inhibitors of the GAD2 enzyme will interfere with the formation of GABA and can be considered as useful drugs for treating obesity, alone or in association with other treatments.

The invention also relates to a method for screening potential obesity
5 therapeutics which comprises: combining (i) a GAD2 binding partner, (ii) a GAD2 polypeptide and (iii) a compound suspected of being a obesity therapeutic and determining the amount of binding of the GAD2 polypeptide to its binding partner.

In a particular embodiment, said binding partner is L-glutamic acid.

The invention also relates to a method for screening potential obesity
10 therapeutics which comprises: combining (i) a *gad2* gene binding partner, (ii) a *gad2* gene and (iii) a compound suspected of being a obesity therapeutic and determining the amount of binding of the *gad2* gene to its binding partner. In this embodiment, the term "*gad2* gene" must be understood as including the 5' flanking region in the *gad2* locus, which comprises the polymorphisms of the invention,
15 especially -243 A>G.

In particular, said *gad2* gene binding partner is IK2 (Ikaros 2), the amino acid sequence of which is represented by SEQ ID N° 3.

The methods for assessing the binding of a compound to a nucleic acid or a protein are well known in the art, and are preferably performed *in vitro*. A method
20 to achieve such a goal may be to link the nucleic acid or the protein to a solid support on which the compound to test is flown, and to check the recovery of the compound after passage on the support. By adjusting parameters, it is also possible to determine the binding affinity. The compounds may also be found by other methods including FRET, SPA... when the compounds and the nucleic acid or
25 protein are labeled. The assay may also be performed on the cells containing the nucleic acid of the invention, for example on a vector according to the invention, and/or expressing the protein according to the invention. This also gives the information of the capacity of the compound to go through the membrane and penetrate within cells. These cells can be bacterial cells, or mammalian cells.

30 The method of the invention also allows the screening, detection and/or identification of compounds able to inhibit the biological activity of the GAD2 protein, and in particular the increase of the amount of produced GABA.

The present invention thus allows the detection, identification and/or screening of compounds that may be useful for the treatment of diseases where V(D)J recombination and/or DNA repair is involved. Nevertheless, the compounds identified by the method according to the invention, in order to be used in a therapeutic treatment, may need to be optimized, in order to have a superior activity and/or a lesser toxicity.

Indeed, the development of new drugs is often performed on the following basis:

- 10 - screening of compounds with the sought activity, on a relevant model, by an appropriate method,
- selection of the compounds that have the required properties from the first screening test (here, modulation of GAD2 or GABA production),
- 15 - determination of the structure (in particular the sequence (if possible the tertiary sequence) if they are peptides, proteins or nucleic acids, formula and backbone if they are chemical compounds) of the selected compounds,
- 20 - optimization of the selected compounds, by modification of the structure (for example, by changing the stereochemical conformation (for example passage of the amino acids in a peptide from L to D), addition of substituents on the peptidic or chemical backbones, in particular by grafting groups or radicals on the backbone, modification of the peptides (see in particular Gante "Peptidomimetics", in Angewandte Chemie-International Edition Engl. 1994, 33. 1699-1720),
- 25 - testing and screening of the "optimized" compounds on appropriate models that are often models nearer to the studied pathology. At this stage, one would often use animal models, in particular rodents (rats or mice) or dogs or non-human primates,
- 30 that are good models of obesity, and to look for the phenotypic changes in said models after administration of the compound.

The present invention also encompasses the compounds that have been optimized after following the steps or equivalent steps as described.

The invention also relates to a pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound identified by a method according to the invention, and to the use of a compound identified by a method
5 according to the invention for the manufacture of a drug intended to treat and/or prevent obesity, especially morbid obesity.

The invention also relates to a method for the therapy of obesity, in particular morbid obesity, comprising administration of a compound or a pharmaceutical composition of the invention.

10 In order to decrease the activity of the *gad2* gene and protein, it is possible to use antisense molecules or SiRNA, in particular complementary to the mRNA of *gad2*, in a pharmaceutical composition for treating obesity.

The invention also relates to the use of a compound as defined above or a antisense molecules or SiRNA for the modulation of insulin secretion.

15 The invention relates to a method for the therapy of obesity, comprising administration of anti-*gad2* antisense molecule or any means to decrease the amount of GAD2 protein. The person skilled in the art is aware of the means to design antisense molecules, and of the modifications that can be brought to the backbones of the molecules (phosphorothioates, methylphosphonates...).

20 Antisense polynucleotide sequences are useful in preventing or diminishing the expression of the *gad2* gene, as will be appreciated by those skilled in the art. For example, polynucleotide vectors containing all or a portion of the *gad2* gene (or other sequences from the *gad2* locus, especially the 5' flanking region) may be placed under the control of a promoter in an antisense orientation and introduced
25 into a cell. Expression of such an antisense construct within a cell will interfere with *gad2* transcription and/or translation.

Alternatively, a "sense" strategy may be foreseen, where a nucleic acid oligonucleotide or probe comprising part of the 5' region of the *gad2* gene (especially comprising the -243 A>G variant at nucleotide 2137 of SEQ ID N° 2) is
30 introduced within the cells, in order to be competitor for binding of the nuclear factors activating transcription. The size of the fragment of the 5' flanking region of the *gad2* gene that can be used in the sense strategy is preferably about 50-150 bases.

The invention also relates to new animal models useful for studying obesity, where expression of the *gad2* gene is increased. In particular, expression of this gene can be increased only conditionally, using promoters that are either site- or
5 time-specific, or inducible promoters. It is thus possible to increase *gad2* expression only in the pancreas of the animals according to the invention, or in the brain. The methods to obtain animals according to the invention are known by the persons skilled in the art, and are useful in particular for testing some drugs that can be identified according to the methods of the invention.

10 The insertion of a construct in the genome of an animal to obtain a transgenic animal may be performed by methods well known by the artisan in the art, and can be either random or targeted. In a few words, the person skilled in the art will construct a vector containing the sequence to insert within the genome, with an appropriate promoter, and a selection marker (for example the gene coding for
15 the protein that gives resistance to neomycine), and may have it enter in the Embryonic Stem (ES) cells of an animal. The cells are then selected with the selection marker, and incorporated into an embryo, for example by microinjection into a blastocyst, that can be harvested by perfusing the uterus of pregnant females. Reimplantation of the embryo and selection of the transformed animals, followed
20 by potential back-crossing makes it possible to obtain such transgenic animal. To obtain a "cleaner" animal, the selection marker gene may be excised by use of a site-specific recombinase, if flanked by the correct sequences.

The invention thus relates to a transgenic non-human mammal having
25 integrated into its genome the nucleic acid sequence of the *gad2* gene or the coding sequence thereof, operatively linked to regulatory elements, wherein expression of said coding sequence increases the level of the GAD2 protein and/or the GABA pool in said mammal relative to a non-transgenic mammal of the same species.

The *gad2* sequence foreseen for the preceding embodiment may be a human
30 *gad2* gene sequence introduced within the genome of the animal of the invention, or the endogenous *gad2* gene sequence the promoter of which has been modified in order to induce overexpression. For example, the *gad2* coding sequence for mouse is known and may be found in GenBank under number NM_008078. Other

endogenous *gad2* genes in other animals may be identified using the homologies between sequences.

Furthermore, the invention also relates to a transgenic non-human mammal whose genome comprises a disruption of the endogenous *gad2* gene, as an animal
5 model for testing links between GAD2 and obesity. In particular, said disruption comprises the insertion of a selectable marker sequence, and said disruption results in said non-human mammal exhibiting a defect in GABA level as compared to a wild-type non-human mammal.

In particular, said disruption is a homozygous disruption, and said
10 homozygous disruption results in a null mutation of the endogenous gene encoding GAD2.

US 6,087,555 describes one way of obtaining a knock-out mouse, and the general teaching of this patent is incorporated herein by reference (column 5, line 54 to column 10 line 13). In this patent, it is described an OPG knock-out mouse,
15 but the same method applies to a GAD2 knock-out mouse. The person skilled in the art will also find information in Hogan et al. (Manipulating the Mouse Embryo: a Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY; 1986).

The mammal of the invention is preferably a rodent, especially a rat or a
20 mouse.

DESCRIPTION OF THE FIGURES

Figure 1: schematic representation of the *gad2* gene, and of the frequency of the SNPs identified in the frame of the invention.

25 Figure 2: gel shift assay, testing the binding of nuclear protein in the 5' region of the *gad2* gene, depending of the nature of the nucleotide at position -243. mt = mutant (G); wt = wild type (A).

Figure 3: Effect of -243A>G *gad2* variant on transcriptional activity in β TC3 cells. Relative Luciferase Units are expressed as means $\pm$ S.D.

30

EXAMPLES

Example 1: association between obesity and SNPs

The *Gad2* gene, encodes an isoform of glutamic acid decarboxylase (GAD65), that catalyses the formation of gamma aminobutyric acid (GABA) from L glutamic acid, and is expressed in both brain and pancreatic islets cells. GABA is one of the most powerful inhibitory neurotransmitters of the central nervous system (CNS). GABA modulate the gastrin's and somatostatin's secretion and may stimulate the glucose intake in several tissues (Erdo and Wolff, 1990 J Neurochem.;54(2):363-72.).

Three SNPs (-243 A>G variant (5'UTRI); -1.6kb G>A (SNP 668); -2004 A>T (SNP 669)), located in the 5' flanking region of the *gad2* gene revealed positive association with obesity in morbidly obese subjects.

The DNA fragments bearing these polymorphisms can be amplified with the following sets of primers,

Polymorphisms of the *gad2* gene were genotyped by direct sequencing or by the LightCycler™ technology (Roche, Mannheim, Germany). The LightCycler assay is based on hybridization probes labelled with fluorescent dyes that allow fluorescence resonance energy transfer (Blomeke et al., 1999, *Anal Biochem* , **275**, 93-7). SNP genotyping was carried out using melting curves analysis. PCR are performed in 9700 apparatus (Applied Biosystems, Foster city, USA) before analysis in lightCycler. Sequences of primers used for PCR and for the LightCycler assays are described in the following table.

SNPs	PCR primers
-243 A>G	F: 5'cctcaaagtctctggggtc3' SEQ ID No 4 R: 5'ggtgtcacgcaggaacagaa3' SEQ ID No 5
-1600 G>A	F 5'ctgaggcgtattaggag SEQ ID No 8 R: 5'ctcctaatacgcctcag SEQ ID No 9
-2004 A>T	F: 5'tgtttcaaccactcatccat SEQ ID No 12 R ; 5'agggacagttagctcg SEQ ID No 13

SNPs	Primers for Light cycler assay
------	--------------------------------

-243 A>G	Red640-gtctcttttaaagctccccggct SEQ ID No 6 cgggctccgaggacccttaggtagtccc-F SEQ ID No 7
-1600 G>A	Red640-ggaaagcagccgcctc SEQ ID No 10 tggaaatgacaggcgctctggccaggcgcg-F SEQ ID No 11
-2004 A>T	Red640-acagcctggtacagactt SEQ ID No 14 tgagttttcgaccacccgggctc-F SEQ ID No 15

(F represents the fluorescein tag).

5 PCR amplifications were performed in a final reaction volume of 20 μ l PCR buffer, containing 50 ng human genomic DNA, 10 pmol of each primer, 2,5 mmol/l MgCl₂, 2,5 mmol/l of dNTP, and 0,2 U of Taq Gold polymerase. The thermal cycling conditions for the PCR product were : 1 cycle 95°C 12 min ; 35 cycles, 95°C 15 sec, 55°C 15 sec, 72 °C 30 sec ;1 cycle 72°C 10 min ; 1 cycle 15°C 15
10 min.

In addition, in order to study the restrained eating and "latent obesity", cognitive restraint of eating, disinhibition and hunger were analyzed according the "Three factor eating questionnaire or TFEQ" (Stunkard AJ and Messick S, 1985 J
15 Psychosom Res; 29(1):71-83.).

Association studies were performed in 369 morbidly unrelated obese patients (mean BMI: 47.3 $\pm$ 7.4 kg/m²; mean age: 46 $\pm$ 12 years; women/men, 294/75).

A set of 381 unrelated non obese non diabetic subjects (mean BMI: 22.8 $\pm$ 2.44 kg/m²; mean age: 58.3 $\pm$ 14.1 years; women/men, 228/152) was used as a
20 control group. Table 1 shows genotype distribution and allele frequencies of the 3 SNPs (-243 A>G variant (5'UTRI); -1.6kb G>A (SNP 668); -2004 A>T (SNP 669)).

25 ***Table 1 .Genotype distribution and allele frequencies of 242 A>G, 1.6kb G>A and 1. 7kb A>T SNPs***

Codominant Model	Morbidly obeses	Controls	p-value
------------------	-----------------	----------	---------

		BMI> 40				
SNP	Geno-type	number of geno-types	Allele Freq.	number of geno-types	Allele Freq.	
5'UTR: -243 A>G	AA AG GG	233 117 15	A:79.9% G:20.1%	270 92 12	A:84.5% G:15.5%	p=0.05
SNP668: -1.6kb G>A	GG GA AA	229 113 14	G:80.2% A:19.8%	255 17 10	G:84.8% A:15.2%	p=0.06
SNP669: -2004 A>T	AA AT AA	221 105 14	A:80.4% T:19.6%	254 9 13	A:83.8% T:16.2%	p=0.19
Dominant Model		Morbidly obese BMI> 40		Controls		<i>p-value</i>
SNP	Geno-type	number of geno-types	Allele Freq.	number of geno-types	Allele Freq.	
5'UTR: -243 A>G	AA AG/GG	233 132	A:79.9% G:20.1%	270 104	A:84.5% G:15.5%	p=0.004
SNP668: -1.6kb G>A	GG GA/AA	229 127	G:80.2% A:19.8%	255 97	G:84.8% A:15.2%	p=0.02
SNP669: -2004 A>T	AA AT/AA	221 119	A:80.4% T:19.6%	254 102	A:83.8% T:16.2%	p=0.07

Under codominant and dominant model, the -243 A>G and the -1.6kb G>A SNP were associated with morbid obesity (respective p values of 0.004 and 0.02 under a dominant model). A trend toward association was observed for the -2004 A>T variant.

The relative risk of these 3 SNPs was estimated: O.R = 1.55 (95% CI [1.14 2.12]) (UTR5I; -243); O.R = 1.45 (95% CI [1.06 2]) (SNP668; -1.6kb); O.R = 1.34 (95% CI [0.97 1.84]) (SNP669; -2004).

In order to replicate these results, the 3 SNPs were genotyped in another set of 316 unrelated morbidly obese subjects. Similar result was obtained for the -243 A>G (under dominant model, p = 0.009) and a trend toward was obtained for the -1.6kb G>A SNP (under dominant model, p = 0.06).

Analysis of variance for obesity related phenotypes was performed (BMI, leptin, percent fat mass, insulinemia...) and significant association between the 3 SNPs and the three factors of eating behavior was found.

To test the human eating behavior, the subjects filled in the TFEQ (Three Factor Eating Questionnaire) questionnaire established by Stunkard et al. (*op. cit.*). The analysis of variance for three stable factors measured by TFEQ: cognitive restraint of eating (Qres), disinhibition (Qdis) and hunger (Qhun) is show in table 2.

5

Table 2 shows the results obtained for the -243 A>G (5'UTR) variant. Similar results were obtained for the -1.6kb G>A (SNP 668) and the -2004 A>T (SNP 669) variants.

Table 2 Analyses of variance with fond intake behavior parameters.

-243 A>G (5'UTR)				
	AA	AG	GG	P
N	233	117	15	
Age	46.02±0.78	47.82±1.1	39.9±3.1	0.04
Age-Pmax	43.5±0.79	44.3±1.1	35.76±3.1	0.03
Qres	9.53±0.31	9±0.45	6.53±1.28	0.06
Qdis	8.38±0.24	8.71±0.34	10.9±0.96	0.03
Qhun	5.29±0.24	6.49±0.35	7.95±0.95	0.001

10

Using a codominant model, it was found that the GG carriers presented a lower restriction score than heterozygous and wild type subjects (pvalue = 0.06). They also presented a higher disinhibition (pvalue = 0.03) and a higher hunger scores (pvalue = 0.001) than heterozygous and wild type subjects. Furthermore, it was observed that GG carriers are younger (pvalue = 0.04) and seem to reach a maximal weight in early ages than AG and AA carriers (pvalue = 0.03). These data suggest that alterations of feeding behavior by *gad2* variants can contribute to the development of younger onset of morbid obesity.

20 **Example 2: Functional study of a promoter variant of *gad 2* gene**

To search for potential binding sites, the sequence of the 5' flanking region of the *gad2* gene was submitted to the transfac server: <http://transfac.gbf.de/cgi-bin/mat>.

In silico analyses showed that the -243 A>G (located at nucleotide 2137 of SEQ ID N° 2) and the -1.6kb G >A (located at nucleotide 780 of SEQ ID N° 2) were located near a predicted Ikaros 2 (IK2) response element site. IK2 is a

25

transcription factor that is highly expressed in human lymphocytes, and its amino acid sequence is represented by SEQ ID N° 3.

In order to test if the -243 A>G variant alters nuclear protein binding to the DNA, a gel shift assay using primers with sequences of the wild type and mutated
5 site and a nuclear extract from MIN6 cells was performed (Figure 2).

Results of the gel shift assay showed that there is *in vitro* binding of nuclear proteins to the IK2 responsive element site. Apparently, the nuclear proteins have a higher affinity to the response element G variant (lire 6 versus 1). Similar result were obtained with competition of the A and G allele (lire 2 vs 3; 6 vs 8; 7 vs 9).

10 To investigate if the allelic variant at position -243 influences GAD2 transcriptional level, transient cotransfections using firefly luciferase reporter construct were performed to measure proximal promoter activity of wild type and variant promoters in β TC3 cells (murine insulinoma cell line). Renilla vector was used to normalize transfection efficiency. The transcriptional activity of -243A>G
15 mutant construct was 8.61 times higher compared to the wild type construct (n=8, p<0.0001) (Figure 3)

The observed increased transcriptional activity induced by the G allele of the -243 A>G is in concordance with the genetic results

- the association of the -243 A>G variant with obesity (p=0.004, O.R
20 = 1.55 (95% CI [1.14-2.12])
- The GG bearers have a lower food restriction score (p = 0.06), a higher disinhibition score (p = 0.03) and a higher hunger score parameter (p = 0.001).

These results indicate that the binding of nuclear proteins (potentially the
25 IK2 transcription factor), in presence of variant allele, was increased and may transactivate the Gad2 gene, and thus the GABA pool. Therefore, orexigenic effect of GABA might be increased and might alter feeding behaviour and contribute to the development of morbid obesity for G carriers of the -243 A>G variant.

The result may be generalized to the other SNPs, that are also close to IK2
30 response element.

The evidence presented in this application indicates involvement of the GABA pathway in obesity in human. This is an important step towards a better

understanding of the molecular mechanisms leading to common forms of obesity. It seems clear that the GABAergic neurons are involved in the integration of signals modulating food intake. The identification of SNPs in the 5' region of the *gad2* gene and the demonstration that their presence modulates the expression of a key enzyme (GAD2), which in turn will modify the GABA pool opens new perspective for drugs against obesity.

Identification of a protective haplotype (for morbid obesity) including the most frequent alleles of SNP +61450 C>A, and +83897 T>A

10

Example 3: Identification of a protective haplotype (for morbid obesity) including the most frequent alleles of SNP +61450 C>A, and +83897 T>A

Haplotype analyses of SNPs -243 A>G , + 84 G>A , +61450 C>A and +83897 T>A were then performed by both HTR and PM+EH+ methods. Haplotypes including SNP + 84 G>A with each of the three remaining SNPs did not improve association with morbid obesity and indeed association of SNP + 84 G>A resulted from its LD with other three SNP (data not shown). Thus, SNP + 84 G>A was excluded from further haplotype analyses. Haplotype structures including the three SNPs, -243 A>G, +61450 C>A, and +83897 T>A were then investigated in the 575 unrelated morbidly obese patients with familial history of obesity and in the 646 non obese subjects. Among the 8 possible haplotypes defined by SNPs -243, +61450 and +83897, only 6 haplotypes displayed a frequency >1% and their combined prevalence encompassed all but 2% of the haplotypes seen in the population (table 3).

Table 3 : haplotype analysis of the obese status in 575 morbidly obese and 646 control subjects. Haplotypes covering three (-243, +61450, +83897) and two (+61450, +83897) SNPs have been investigated. Family-based association test for each haplotype. A positive Z_{norm} means that there is an excess of allele in affected offspring.

Haplotypes			Case/control Test			Family-Based Association Test	
-243 A>G	+61450 C>A	+83897 T>A	Non obese	Morbidly obese	p-value	Znorm	p-value
1 _(A)	1 _(C)	1 _(T)	70.6	64.3	0.003	-1.92	0.05
2 _(G)	2 _(A)	2 _(A)	15	16	0.40	1.56	0.12
1 _(A)	2 _(A)	1 _(T)	11	12.8	0.023	1.15	0.25
2 _(G)	2 _(A)	1 _(T)	0.9	2.24	0.025		
2 _(G)	1 _(C)	2 _(A)	0.09	1.3	0.003		
1 _(G)	1 _(C)	2 _(A)	0.2	1	0.87		
	1 _(C)	1 _(T)	71.2	65.3	0.0049	-1.94	0.05
	2 _(A)	2 _(A)	16.6	17.1	0.59	1.73	0.08
	2 _(A)	1 _(T)	11.8	15.11	0.044	1.14	0.25
	1 _(C)	2 _(A)	0.4	2.4	0.0003		

1 wild allele 2 variant allele ; The corresponding nucleotides are shown as subscripts in parentheses

- 5 Comparison of haplotype frequencies performed by haplotype trend regression (HTR) between cases and controls showed evidence for association with obesity with an empirical pvalue of 0.0004. This positive result was ascertained by a PM+EH+ analysis (p=0.0002). Frequencies of haplotypes bearing the wild type alleles (A-C-T) were significantly higher in non-obese compared to the morbidly
- 10 obese group (table1). It is noteworthy that the risk G allele at SNP -243 A>G was present on several haplotypes with frequencies lower than 1% which cannot be taken into account for the haplotype analysis. SNPs -243, +61450 and +83897 were in strong linkage disequilibrium, the chi2 between these markers were ranging from 556 to 1265, thus p values were <0.00001.
- 15 In addition posterior probabilities of haplotype accuracy, as assayed by SNPHAP, were >0.98 for 98% of the subjects included in the study. For the remaining 2% of subjects, posterior probabilities were ranging from 0.88 to 0.98. Moreover on a background wild type CC for SNP +61450 C>A or TT for SNP +83897 T>A, association of SNP -243 A>G with morbid obesity remained significant (p=0.01

and $p=0.03$ respectively). The independent effect of -243 A>G was confirmed by haplotype analysis of SNPs +61450 C>A, and +83897 T>A that presented a significant association with morbid obesity, overall permutation showing an empirical p -value < 0.0001 . Estimated frequencies of haplotype bearing the wild
5 type alleles (C-T) remained higher in the non-obese compared to the morbidly obese group ($p=0.0049$). Thus the (C-T) haplotype displayed a “protective” effect against obesity (OR=0.81 95% CI [0.681-0.972])

**Example 4: Linkage, familial association and association with the evidence of
10 linkage of GAD SNPs.**

Familial association and association with the evidence of linkage were investigated in the 188 nuclear families (612 individuals). First, as expected in a region of linkage, the SNPs -243 A>G , +61450 C>A and +83897 T>A showed significant
15 linkage with a binary obese status, displaying MLS of respectively 2.54, 1.86 and 4.54 (data not shown). The SNPs of GAD certainly show linkage with obesity and that they are, therefore, worth investigating for family based association tests.

Familial-Based Association Test (FBAT) was used to detect association in our established linkage context. In single SNP analyses, we observed an association and
20 an excess of wild type alleles in non affected offspring for SNPs +61450 C>A, and +83897 T>A ($Z = -2.17$ $p= 0.03$ and $Z = -2.09$ $p= 0.03$ respectively) and a trend towards association and excess of G allele for SNP -243 A>G in affected offspring ($Z=1.87$, $p= 0.06$). For haplotype analysis of SNPs +61450 C>A and +83897 T>A, the global test for association with obesity was significant ($\chi^2 = 7.637$, p -
25 value=0.02). The protective wild type (C-T) haplotype was in excess in non affected offspring ($Z = -1.94$, p -value = 0.05) (table 1).

A significant association with the evidence of linkage was observed for SNP +61450 C>A. 17 nuclear families, with concordant affected sibpairs for (A-A) genotype, displayed a lod-score of 4.13, $p=0.02$ (as this lod-score was reached 20
30 times out of 1000 simulations, assessing a C allele frequency of 0.72, value in the control cohorts). When considering a C allele frequency of 0.68 (value in the morbidly obese cohorts) a p value of 0.06 was observed. Remaining sibpairs non-

concordant for this genotype, displayed a lod score of 1.75. Thus, it is impossible to exclude that SNP +61450 C>A explains the observed linkage.

Example 5: Modulation of insulin secretion by GAD2 SNPs.

5

As GABA release from β cells was suggested to strongly inhibit insulin secretion (Shi et al., 2000), we looked in non diabetic control subjects for a potential effect of *GAD2* SNPs on fasting insulin and on the β -cell function (HOMA-B%) assessed with the homeostasis model. We found that subjects homozygous (AA) for +83897
10 T>A showed lower fasting insulin levels and HOMA B indexes (pvalues for Kruskal-Wallis test: 0.0091 and 0.01 respectively for fasting insulin and HOMA B) (figure 6) suggesting a deleterious effect of *GAD2* SNPs on insulin secretion, probably through an increase of the GABA pool in pancreatic β cells mediated by GAD65 higher enzymatic activity.

15

20

SEQUENCE LISTING

<110> CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)

<120> METHOD OF DIAGNOSIS OF OBESITY

<130> D20470

<150> EP 02 293 085

<151> 2002-12-13

<160> 15

<170> PatentIn Ver. 2.1

<210> 1

<211> 1758

<212> DNA

<213> Homo sapiens

<220>

<223> gad2 gene

<400> 1

```

atggcatctc cgggctctgg ctttttgggtct ttccgggtcgg aagatggctc tgggggattcc 60
gagaatcccc gcacagcgcg agcctgggtgc caagtggctc agaagttcac gggcggcatc 120
ggaaacaaac tgtgcgccct gctctacgga gacgccgaga agccggcgga gagcggcggg 180
agccaacccc cgcggggccgc cgcccgggaag gccgcctgcg cctgcgacca gaagccctgc 240
agctgctcca aagtggatgt caactacgcg tttctccatg caacagacct gctgccggcg 300
tgtgatggag aaaggcccac tttggcggtt ctgcaagatg ttatgaacat tttacttcag 360
tatgtggtga aaagtttcga tagatcaacc aaagtgattg atttccatta tcctaattgag 420
cttctccaag aatataattg ggaattggca gaccaaccac aaaatttgga ggaaattttg 480
atgcattgcc aaacaactct aaaatatgca attaaaacag ggcattcctag atacttcaat 540
caacttttcta ctggtttgga tatggttgga ttagcagcag actggctgac atcaacagca 600
aatactaaca tgttcaccta tgaaattgct ccagtatattg tgcttttgga atatgtcaca 660
ctaaagaaaa tgagagaaat cattggctgg ccagggggct ctggcgatgg gatattttct 720
cccgggtggcg ccatatctaa catgtatgcc atgatgatcg cacgctttta gatgttccca 780
gaagtcaagg agaaaggaat ggctgctctt ccagggtcca ttgccttcac gtctgaacat 840
agtcattttt ctctcaagaa gggagctgca gccttaggga ttggaacaga cagcgtgatt 900
ctgattaaat gtgatgagag agggaaaatg attccatctg atcttgaaag aaggattctt 960
gaagccaaac agaaaggggt tgttcctttc ctctgtgagt ccacagctgg aaccaccgtg 1020
tacggagcat ttgacccctt cttagctgtc gctgacattt gcaaaaagta taagatctgg 1080
atgcatgtgg atgcagcttg ggggtggggga ttactgatgt cccgaaaaca caagtggaaa 1140
ctgagtggcg tggagagggc caactctgtg acgtggaatc cacacaagat gatgggagtc 1200
cctttgagct gctctgctct cctgggttaga gaagagggat tgatgcagaa ttgcaaccaa 1260
atgcatgcct cctacctctt tcagcaagat aaacattatg acctgtccta tgacactgga 1320
gacaaggcct tacagtgcgg acgccacggt gatgttttta aactatggct gatgtggagg 1380
gcaaagggga ctaccgggtt tgaagcgcat gttgataaat gtttggagtt ggcagagtat 1440
ttatacaaca tcataaaaaa ccgagaagga tatgagatgg tgtttgatgg gaagcctcag 1500
cacacaaatg tctgcttctg gtacattcct ccaagcttgc gtactctgga agacaatgaa 1560
gagagaatga gtcgcctctc gaagggtggc ccagtgatta aagccagaat gatggagtat 1620
ggaaccacaa tggtcagcta ccaacccttg ggagacaagg tcaatttctt ccgcatggtc 1680
atctcaaacc cagcggcaac tcaccaagac attgacttcc tgattgaaga aatagaacgc 1740
cttggacaag atttataa

```

<210> 2

<211> 2382

<212> DNA

<213> Homo sapiens

<220>

<223> 5' flanking region of gad2 gene nucleotides

<220>

<223> R = G or A

<220>

<223> Y = T or C

<220>

<223> M = A or C

<220>

<223> W = A or T

<220>

<223> S = G or C

<400> 2

```

gaaaaaaaaa tcagttaaat tcaggtgttt taatccgttt cttcttttggg ggtttttgtgt 60
gatttaaacg cttgctttta agaacccttta tgttttcaac cactcatcca tagtagaaaa 120
gttctgcaac cctagactgc tggcttgaag gaaaaccttt gcaggatttg atatggattt 180
caacaaagaa ccagcctctg cgaggctgga gagagctgcg gagctgccat gcctgaagtg 240
cagatggctg aaccacaagt ctttaggttt ccggagttgt tattgtggtg acctagagtg 300
tcagagccag gagagcaaga aagaggagcc aaactgagcc ctgagttttc gaccaccg 360
gctcccacag cctggwacag acttcaccta gcacgctcag tgccagcctt cggcaggacg 420
ctatcaacgc ccgactggwt tcytgctctc atcctggcgc ctgggcccag ttgccatagt 480
gtggatccca tgactcctca gggaacccct ggactcaggc acgcgagaag aagacagcgc 540
tttgtggaga gaattgacca gggacagtta tgctcgagca cacaggactt gggcctgtat 600
gcgtccagca tgggccccag gatgtccctt ctaagcgagg gtcgaggggt gctcgcccag 660
acgggatccc cgggtctctg ctttgtttagc agctttggtg gctggttcag gaggtcagag 720
aaataaaaacg acttgtgaac acaatggaaa tgacaggcgc tctggccagg cgcggggaar 780
gcagccgcct cgggaagccg acctcagccc ttccctctct ctcctccct ccgtctcccc 840
cagagccccg gagctccgag gtgcacttga agttcatctc cactgccagg agaacgcagc 900
gcaaactgtc aaagggctcc caatccttag ggcgtcctcc ctgtctgcaa tagctttttg 960
tagaaaggaa atcatcagaa mgattctgac tttctcctcc tttctttatt agaaaaagag 1020
aaaccgcctc ctaatacgcc tcagagagaa ccaatctcgc gcttccgggt caccgcctac 1080
cgcgaaagatt ctctgggggc gagggggggc attggtttga agccccttaa aacgagggcc 1140
ctgcaggcga tgctttcttt cctactcgga tttgtaaagc cgagattgct tagttggaaa 1200
ccctgttctc ccctcccagg cgcacacaga tcccccttac acgcaagcag cgggcgcttc 1260
cacgcctccg cgggccaagg tcaccaaatag ccctgattcc atccccacc cgccatcaat 1320
cctgccgact ctggccgctc tgccctcatc tcttccaaga agtttccatt cgttttattt 1380
ttttttcccc agcccagagt cctcagtaga ctccagcgtg gatttttaatt gcctcaatca 1440
gcagtcattc tccccagccg tcaactcagag cctggacggt ggggtcccgc atctagccct 1500
tggctacgca ggaacggtgc gccccgggt acggcgcggt tcagcaggca ggcgtcaggt 1560
tctaccaagg cgctgaaatg agcccatcag cgggtaggag cccttcccc gccgtcccct 1620
ccccaggctc gtgaacggcg cctgatgccc gccggggcg cgagctctcg aggtcgcagt 1680
gacctcagca cctgcttgga ggaaaacggc gcgggaacce cgcttccctt ccctcagctg 1740
gagccagacc tcaaacaaaa cccaatcga tgcacacaga aaactcctct gggccacgct 1800
tccgcctcgc ccgaggtctc ccagctctgc ccctcgctga cgctggcgcg cagcsgctgt 1860
ggcagcaccg gggacagcgg ccgcccgcac ttcccgctc tggctcgccc gaggacgcgc 1920
tggcacgcct cccacccct cactctgact ccagctggcg tgcatggtct gcctcgcatc 1980
ctcacgactc agctccctcc ctctctcgtg tttttttcct ccgcccctc ctcatcctc 2040
cccactgggc tccctttccc tcaaatgctc tggggctctc cgcgctttcc tgagtccggg 2100
ctccgaggac ccttaggtag tcccggtctc ttttaargct ccccggttc caaagggttg 2160
ccacgtccct aaaccctgtc tccagctcgc atacacacac gcacagacac gcacgttttc 2220
tgttcctgcg tgacaccgc cctcgccgct cggccccgc ggtccccgc cggtgccctc 2280
ctcccgccac acgggcacgc acgcgcgcgc agggccaagc ccgaggcagc tcgcccgcag 2340
ctcgcactcg caggcgacct gctccagctc ccaaagccga tg 2382

```

<210> 3

<211> 519

<212> PRT

<213> Homo sapiens

<220>

<223> DNA-binding protein Ikaros (Lymphoid transcription factor LyF-1)

<400> 3

Met	Asp	Ala	Asp	Glu	Gly	Gln	Asp	Met	Ser	Gln	Val	Ser	Gly	Lys	Glu
1				5				10						15	

Ser	Pro	Pro	Val	Ser	Asp	Thr	Pro	Asp	Glu	Gly	Asp	Glu	Pro	Met	Pro
			20					25					30		

Ile	Pro	Glu	Asp	Leu	Ser	Thr	Thr	Ser	Gly	Gly	Gln	Gln	Ser	Ser	Lys
		35					40					45			

Ser	Asp	Arg	Val	Val	Ala	Ser	Asn	Val	Lys	Val	Glu	Thr	Gln	Ser	Asp
	50					55					60				

Glu	Glu	Asn	Gly	Arg	Ala	Cys	Glu	Met	Asn	Gly	Glu	Glu	Cys	Ala	Glu
65					70					75					80

Asp	Leu	Arg	Met	Leu	Asp	Ala	Ser	Gly	Glu	Lys	Met	Asn	Gly	Ser	His
			85						90					95	

Arg	Asp	Gln	Gly	Ser	Ser	Ala	Leu	Ser	Gly	Val	Gly	Gly	Ile	Arg	Leu
		100						105					110		

Pro	Asn	Gly	Lys	Leu	Lys	Cys	Asp	Ile	Cys	Gly	Ile	Ile	Cys	Ile	Gly
		115					120					125			

Pro	Asn	Val	Leu	Met	Val	His	Lys	Arg	Ser	His	Thr	Gly	Glu	Arg	Pro
	130					135					140				

Phe	Gln	Cys	Asn	Gln	Cys	Gly	Ala	Ser	Phe	Thr	Gln	Lys	Gly	Asn	Leu
145					150					155					160

Leu	Arg	His	Ile	Lys	Leu	His	Ser	Gly	Glu	Lys	Pro	Phe	Lys	Cys	His
			165						170					175	

Leu	Cys	Asn	Tyr	Ala	Cys	Arg	Arg	Arg	Asp	Ala	Leu	Thr	Gly	His	Leu
		180						185					190		

Arg	Thr	His	Ser	Val	Gly	Lys	Pro	His	Lys	Cys	Gly	Tyr	Cys	Gly	Arg
		195					200					205			

Ser	Tyr	Lys	Gln	Arg	Ser	Ser	Leu	Glu	Glu	His	Lys	Glu	Arg	Cys	His
	210					215					220				

Asn	Tyr	Leu	Glu	Ser	Met	Gly	Leu	Pro	Gly	Thr	Leu	Tyr	Pro	Val	Ile
225					230					235					240

Lys	Glu	Glu	Thr	Asn	His	Ser	Glu	Met	Ala	Glu	Asp	Leu	Cys	Lys	Ile
				245					250					255	

Gly	Ser	Glu	Arg	Ser	Leu	Val	Leu	Asp	Arg	Leu	Ala	Ser	Asn	Val	Ala
			260					265					270		

4/7

Lys Arg Lys Ser Ser Met Pro Gln Lys Phe Leu Gly Asp Lys Gly Leu
 275 280 285
 Ser Asp Thr Pro Tyr Asp Ser Ser Ala Ser Tyr Glu Lys Glu Asn Glu
 290 295 300
 Met Met Lys Ser His Val Met Asp Gln Ala Ile Asn Asn Ala Ile Asn
 305 310 315 320
 Tyr Leu Gly Ala Glu Ser Leu Arg Pro Leu Val Gln Thr Pro Pro Gly
 325 330 335
 Gly Ser Glu Val Val Pro Val Ile Ser Pro Met Tyr Gln Leu His Lys
 340 345 350
 Pro Leu Ala Glu Gly Thr Pro Arg Ser Asn His Ser Ala Gln Asp Ser
 355 360 365
 Ala Val Glu Asn Leu Leu Leu Leu Ser Lys Ala Lys Leu Val Pro Ser
 370 375 380
 Glu Arg Glu Ala Ser Pro Ser Asn Ser Cys Gln Asp Ser Thr Asp Thr
 385 390 395 400
 Glu Ser Asn Asn Glu Glu Gln Arg Ser Gly Leu Ile Tyr Leu Thr Asn
 405 410 415
 His Ile Ala Pro His Ala Arg Asn Gly Leu Ser Leu Lys Glu Glu His
 420 425 430
 Arg Ala Tyr Asp Leu Leu Arg Ala Ala Ser Glu Asn Ser Gln Asp Ala
 435 440 445
 Leu Arg Val Val Ser Thr Ser Gly Glu Gln Met Lys Val Tyr Lys Cys
 450 455 460
 Glu His Cys Arg Val Leu Phe Leu Asp His Val Met Tyr Thr Ile His
 465 470 475 480
 Met Gly Cys His Gly Phe Arg Asp Pro Phe Glu Cys Asn Met Cys Gly
 485 490 495
 Tyr His Ser Gln Asp Arg Tyr Glu Phe Ser Ser His Ile Thr Arg Gly
 500 505 510
 Glu His Arg Phe His Met Ser
 515

<210> 4

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

 <223> Description of Artificial Sequence: Primer to
 amplify SNP - 243

<400> 4

cctcaaattgc tctggggctc

<210> 5
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Primer to
amplify SNP - 243

<400> 5
ggtgtcacgc aggaacagaa

20

<210> 6
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Primer to
amplify SNP - 243

<400> 6
gtctctttta aagctccccg gct

23

<210> 7
<211> 28
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Primer to
amplify SNP - 243

<400> 7
cgggctccga ggacccttag gtagtccc

28

<210> 8
<211> 17
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Primer to
amplify SNP - 1.6 kb

<400> 8
ctgaggcgta ttaggag

17

<210> 9
<211> 17
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Primer to

amplify SNP - 1.6 kb

<400> 9

ctcctaatac gcctcag

17

<210> 10

<211> 16

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer to
amplify SNP - 1.6 kb

<400> 10

ggaaagcagc cgcctc

16

<210> 11

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer to
amplify SNP - 1.6 kb

<400> 11

tggaaatgac aggcgctctg gccagggcgcg

30

<210> 12

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer to
amplify SNP - 2004

<400> 12

tgtttttcaac cactcatcca t

21

<210> 13

<211> 17

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer to
amplify SNP - 2004

<400> 13

agggacagtt atgctcg

17

<210> 14

<211> 18

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer to
amplify SNP - 2004

<400> 14

acagcctggt acagactt

18

<210> 15

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer to
amplify SNP - 2004

<400> 15

tgagttttcg accacccggg ctc

23

CLAIMS

- 5 1. A method for diagnosing a predisposition for obesity, and in particular morbid obesity, in a human subject which comprises determining whether there is a germline alteration in the sequence of the 5' flanking region of the *gad2* gene, the coding sequence of which is represented by SEQ ID N° 1, wherein said alteration is the presence of at least one of the following mutations: -243 A>G at nucleotide 2137 of SEQ ID N° 2, -1.6kb G>A
10 at nucleotide 780 of SEQ ID N° 2, -2004 A>T at nucleotide 376 of SEQ ID N° 2, said alteration being indicative of a predisposition to obesity.
2. The method of claim 1, wherein said obesity is morbid obesity.
- 15 3. A method for diagnosing a predisposition for obesity in a human subject, from a sample from said subject, wherein the level of an expression product of the *gad2* gene in said sample is investigated.
- 20 4. The method of claim 3, wherein said expression product is RNA or protein, or GABA.
- 25 5. The method of one of claim 1 to 4 further comprising a step consisting of detecting a protective haplotype for morbid obesity including alleles of SNP +61450 C>A, and +83897 T>A as depicted in SEQ ID No 16 and 17 respectively.
6. A primer or probe for detecting a predisposition for obesity selected from SEQ ID No 4 to 15.
- 30 7. A kit for detecting a predisposition for obesity comprising a set of primers or probes consisting of SEQ ID No 4, 5, 8, 9, 12 and 13 or a set of primers or probes consisting of SEQ ID No 6, 7, 10, 11, 14, and 15.

8. The kit according to claim 7 further comprising a primer or probe allowing detection of a protective haplotype consisting of 10 to 30 consecutive nucleotides of SEQ ID No 16 or 17 or of a sequence complementary thereof.
- 5 9. A method for screening potential obesity drugs which comprises: combining (i) a compound suspected of being an obesity drug, (ii) a GAD2 polypeptide and determining the amount of binding of the GAD2 polypeptide to said compound.
- 10 10. A method for screening potential obesity therapeutics which comprises: combining (i) a GAD2 binding partner, (ii) a GAD2 polypeptide and (iii) a compound suspected of being a obesity therapeutic and determining the amount of binding of the GAD2 polypeptide to its binding partner.
- 15 11. The method of claim 10, wherein said GAD2 binding partner is L-glutamic acid.
- 20 12. A method for screening potential obesity therapeutics which comprises: combining (i) a *gad2* gene binding partner, (ii) a *gad2* gene and (iii) a compound suspected of being a obesity therapeutic and determining the amount of binding of the *gad2* gene to its binding partner.
- 25 13. The method of claim 12, wherein said *gad2* gene binding partner is IK2 (Ikaros 2).
- 30 14. A pharmaceutical composition comprising a pharmaceutically acceptable excipient with a compound identified with the method according to any of claims 9 to 13.
15. Use of a compound identified with the method according to any of claims 9 to 13, or of a composition according to claim 14 for the preparation of a drug intended for treatment of obesity, in particular morbid obesity.

16. Use of an antisense molecule or SiRNA complementary to the *gad2* mRNA for the preparation of a drug intended for treatment of obesity, in particular morbid obesity.
- 5 17. The use according to claim 15 or 16 for the modulation of insulin secretion.
18. Use of a sense molecule comprising a fragment of the 5' flanking region of the *gad2* gene, especially comprising the -243 A>G variant (at nucleotide 2137 of SEQ ID N° 2), within said region, for the manufacture of a drug
10 intended for the treatment of obesity.
19. A transgenic non-human mammal having integrated into its genome the nucleic acid sequence of *gad2*, or coding sequence thereof, operatively linked to regulatory elements, wherein expression of said sequence increases
15 the level of the GAD2 protein and/or the GABA pool in said mammal relative to a non-transgenic mammal of the same species.
20. A transgenic non-human mammal whose genome comprises a disruption of the endogenous *gad2* gene, wherein said disruption comprises the insertion
20 of a selectable marker sequence, and wherein said disruption results in said non-human mammal exhibiting a defect in GABA level as compared to a wild-type non-human mammal.
21. The mammal of claim 19 or 20 which is a mouse.
25
22. Use of a mammal according to any of claims 19 to 21, as a model for studying obesity, or for testing potential anti-obesity drugs.




Figure 1




Figure 2




Figure 3